Tevogen (TVGN) Bio announces it has entered into a definitive agreement for up to $50M in financing. This formalizes the binding term sheet previously announced May 10, 2024, the company noted. The financing consists of a combination of a $36M line of credit and a $14M contingent private placement. “We are excited to finalize this agreement with a financing partner who shares our vison and are ready to deploy the funding as pragmatically as possible. We believe this financing together with our business model of efficient operations and innovative thinking will allow us to meaningfully expand our R&D efforts and investments in Tevogen AI. I’m pleased we are taking this significant step to help patients by providing affordable and accessible personalized T cell therapies for large patient populations,” said Dr. Ryan Saadi, Tevogen Bio Founder and CEO.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen receives $1M to accelerate AI-driven drug discovery
- Tevogen expanding collaboration with Microsoft and Databricks
- Tevogen signs letter of intent for new cell therapy manufacturing facility
- AI Daily: OpenAI said to end acquisition talks with Windsurf
- Tevogen.AI builds alpha version of PredicTcell model